Discontinued — last reported Q2 '19
Non-Current Assets
Equity Securities (FV-NI) - Non-Current
Royalty Pharma Equity Securities (FV-NI) - Non-Current increased by 1.1% to $173.27M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 22.8%, from $141.08M to $173.27M. Over 5 years (FY 2020 to FY 2025), Equity Securities (FV-NI) - Non-Current shows a downward trend with a -10.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2018
Last reportedQ2 2019
Metric ID:
equity_securities_fvni_noncurrentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $184.04M | $264.77M | $269.80M | $267.64M | $304.45M | $262.82M | $112.35M | $101.53M | $142.80M | $144.34M | $199.49M | $277.22M | $178.02M | $228.87M | $186.96M | $141.08M | $110.53M | $129.39M | $171.31M | $173.27M |
| QoQ Change | — | +43.9% | +1.9% | -0.8% | +13.8% | -13.7% | -57.3% | -9.6% | +40.6% | +1.1% | +38.2% | +39.0% | -35.8% | +28.6% | -18.3% | -24.5% | -21.7% | +17.1% | +32.4% | +1.1% |
| YoY Change | — | — | — | — | +65.4% | -0.7% | -58.4% | -62.1% | -53.1% | -45.1% | +77.6% | +173.0% | +24.7% | +58.6% | -6.3% | -49.1% | -37.9% | -43.5% | -8.4% | +22.8% |
Range$101.53M – $304.45M
CAGR-1.3%
Avg YoY Growth+3.6%
Median YoY Growth-7.3%
Current Streak3 quarters growth
Equity Securities (FV-NI) - Non-Current at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's equity securities (fv-ni) - non-current?
- Royalty Pharma (RPRX) reported equity securities (fv-ni) - non-current of $173.27M in Q1 2026.
- How has Royalty Pharma's equity securities (fv-ni) - non-current changed year-over-year?
- Royalty Pharma's equity securities (fv-ni) - non-current increased by 22.8% year-over-year, from $141.08M to $173.27M.
- What is the long-term trend for Royalty Pharma's equity securities (fv-ni) - non-current?
- Over 5 years (2020 to 2025), Royalty Pharma's equity securities (fv-ni) - non-current has grown at a -10.5% compound annual growth rate (CAGR), from $298.69M to $171.31M.